CPT 87811: SARS-CoV-2 Immunoassay, Visual Observation - OpenPayer

Summary & Overview

CPT 87811: SARS-CoV-2 Immunoassay, Visual Observation

CPT code 87811 identifies a technical laboratory test: an immunoassay with direct optical (visual) observation to detect SARS‑CoV‑2 (COVID‑19) antigen in a clinical specimen. The code captures the laboratory analyst’s performance of the visual antigen test rather than interpretation or reporting components. Nationally, this code matters because visual immunoassays remain a component of SARS‑CoV‑2 testing workflows in outpatient, urgent care, and laboratory settings, affecting billing, coding consistency, and payer coverage decisions.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical and coding context for 87811, comparisons to related antigen detection codes, and typical sites of service where the test is performed. The summary outlines what is billable under the technical component for visual immunoassays and highlights practical coding considerations relevant to laboratory managers, clinicians ordering tests, and billing professionals.

This publication provides national-level context on clinical use, claims coding alignment, and where 87811 fits alongside similar antigen detection services. Data not available in the input are identified where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareCPT 87811SARS-CoV-2 testingimmunoassayantigen detectionclinical laboratorytechnical componentvisual observationlaboratory billingCOVID-19 testing

Billing Code Overview

CPT code 87811 describes a laboratory immunoassay with direct optical (visual) observation performed by a lab analyst to detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (COVID‑19) in a patient specimen. This service represents the technical laboratory testing portion of a visual immunoassay method used to identify viral antigen.

Service type: Clinical laboratory immunoassay (technical component)
Typical site of service: Clinical laboratory or point-of-care testing location where visual immunoassays are performed

Clinical & Coding Specifications

Clinical Context

A 36-year-old adult presents to a family medicine clinic in late winter with 2 days of fever, sore throat, myalgia, and cough. The clinician documents acute upper respiratory infection and orders a point-of-care immunoassay for SARS–CoV‑2 to determine active infection. A medical assistant collects a nasopharyngeal or nasal specimen per clinic protocol and the specimen is sent immediately to the onsite clinical medical laboratory. A licensed lab analyst performs a direct optical immunoassay (visual read) to detect SARS–CoV‑2 antigen and reports a qualitative positive or negative result in the electronic health record. Results are routed to the ordering internal medicine or family medicine physician for clinical correlation and documentation of diagnosis codes such as J06.9 (acute upper respiratory infection), J10.1 or J11.1 (influenza with other respiratory manifestations), or R05 (cough) as appropriate. Typical workflow includes specimen collection, accessioning, technical performance of the immunoassay by lab personnel, result verification, and final reporting; typical site of service is an ambulatory clinic with an onsite clinical medical laboratory or a freestanding clinical lab that performs rapid antigen immunoassays.

Coding Specifications

Modifier	Description	When to Use

Related Codes

99214

CPT 99214: Office Visit for Established Patients, Moderate Complexity

87635

CPT 87635: Laboratory Detection of SARS-CoV-2 via Nucleic Acid Amplification

99212

CPT 99212: Office Visit for Established Patients, Straightforward Decision Making

99203

CPT 99203: Office Visit for New Patients, Low Complexity

99205

CPT 99205: Office Visit for New Patients, High Complexity

12001

CPT 12001: Simple Repair of Superficial Wounds, ≤2.5 cm

cpt-71047-chest-radiograph-three-views

CPT 71047: Chest Radiograph, Minimum Three Views

12002

CPT 12002: Simple Repair of Superficial Wounds, 2.6–7.5 cm

hcpcs-s9083-urgent-care-global-fee

HCPCS S9083: Global Fee for Urgent Care Center Services

99215

CPT 99215: Office Visit for Established Patients, High Complexity

Showing 1–10 of 43

26

Taxonomy Code	Specialty	Notes
`291U00000X`	Clinical Medical Laboratory	Typical performing provider for technical execution and reporting of the immunoassay.
`207Q00000X`	Family Medicine Physician	Common ordering provider in ambulatory primary care settings; documents clinical indications and interpretation.
`207R00000X`	Internal Medicine Physician	Common ordering and result-reviewing provider, especially for adult patients in outpatient clinics.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J10.1`	Influenza with other respiratory manifestations, seasonal influenza virus identified	Differential diagnosis for acute febrile respiratory illness; testing for SARS‑CoV‑2 helps distinguish viral etiologies.
`J11.1`	Influenza with other respiratory manifestations, virus not identified	Used when clinical influenza is suspected but viral testing does not identify influenza; SARS‑CoV‑2 testing may be performed concurrently.
`J09.X2`	Influenza due to identified novel influenza A virus with other respiratory manifestations	Severe or novel influenza presentations may overlap clinically with COVID‑19; SARS‑CoV‑2 antigen testing is part of the diagnostic workup.
`J06.9`	Acute upper respiratory infection, unspecified	Common presenting diagnosis prompting SARS‑CoV‑2 antigen testing in ambulatory settings.
`R05`	Cough	Symptom code that commonly accompanies respiratory infections and often accompanies testing for SARS‑CoV‑2 antigen.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87428`	Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; SARS‑CoV and SARS‑CoV‑2 and influenza A and B	Alternative or multiplex antigen assay that detects SARS‑CoV‑2 and influenza A/B in a single platform; may be ordered when combined respiratory pathogen antigen testing is needed alongside or instead of a SARS‑CoV‑2–only immunoassay.